logo

For the Inventor, By the Inventor

Rockville, MD, United States of America

Glycomimetics, Inc.


USPTO Granted Patents = 41

% Expired Patents = 14.6


Forward Citations = 450

Loading Chart...
Loading Chart...

24 inventors (with patents filed for the assignee):

goldMedal John L Magnani (39 out of 48 patents)

silverMedal Arun K Sarkar (21 out of 22 patents)

bronzeMedal John Tinsman Patton, Jr (11 out of 12 patents)

4.  Myung-Gi Baek (10 out of 10 patents)

5.  John M Peterson (8 out of 11 patents)

6.  Yanhong Li (6 out of 6 patents)

7.  Beat Ernst (6 out of 13 patents)

8.  Frank Elbert Anderson, Iii (6 out of 10 patents)

9.  Sergei A Svarovsky (4 out of 7 patents)

10.  Leonard M Williams (3 out of 3 patents)

11.  Yusufbhai U Vohra (3 out of 3 patents)

12.  Yusuf U Vohra (2 out of 2 patents)

13.  William E Fogler (2 out of 7 patents)

14.  Indranath Ghosh (2 out of 4 patents)

15.  Jason Nogueira (2 out of 2 patents)


Core Competencies:
E-Selectin Antagonists
Galectin-3 Inhibitors
Heterobifunctional Inhibitors
Glycomimetic Compounds
Acute Myeloid Leukemia
Cardiovascular Disease Treatment
Pan-Selectin Inhibitors
T-Cell Checkpoint Inhibitors
Hematopoietic Cell Mobilization
Sickle Cell Disease Treatment
Prostate Cancer Detection
Selectin-Mediated Function Inhibition

41 patents:

1. 11987598 - E-selectin antagonist compounds, compositions, and methods of use (2024-05-21),
2. 11878026 - Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists (2024-01-23),
3. 11873317 - Galectin-3 inhibiting c-glycosides (2024-01-16),
4. 11845771 - Heterobifunctional inhibitors of E-selectin and galectin-3 (2023-12-19),
5. 11780873 - Highly potent multimeric e-selectin antagonists (2023-10-10),
6. 11712446 - Methods of mobilizing marrow infiltrating lymphocytes and uses thereof (2023-08-01),
7. 11707474 - Methods for treating acute myeloid leukemia and related conditions (2023-07-25),
8. 11548908 - Heterobifunctional inhibitors of E-selectin and galectin-3 (2023-01-10),
9. 11433086 - Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4 (2022-09-06),
10. 11332491 - E-selectin antagonist compounds, compositions, and methods of use (2022-05-17),
11. 11291678 - Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin (2022-04-05),
12. 11197877 - Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists (2021-12-14),
13. 11072625 - Highly potent multimeric e-selectin antagonists (2021-07-27),
14. 11045485 - Glycomimetic inhibitors of PA-IL and PA-IIL lectins (2021-06-29),
15. 10766916 - E-selectin antagonist compounds, compositions, and methods of use (2020-09-08),
GlycoMimetics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs. The company's research and development efforts are centered around the biology of glycans, which are complex carbohydrates that play crucial roles in cellular communication and disease mechanisms. With a diverse pipeline of potential therapeutics targeting various diseases, GlycoMimetics aims to improve patient outcomes and contribute to the advancement of healthcare.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

Glycomimetics, Inc.
41 Patents

#16 in Rockville, MD

#98 in Maryland

#8,416 in US

#16,646 in the World

Rockville, MD (US)
Rockville, MD, United States of America

Glycomimetics, Inc.

Forward Citations = 450

24 inventors:

goldMedal John L Magnani (39 out of 48 patents)

silverMedal Arun K Sarkar (21 out of 22 patents)

bronzeMedal John Tinsman Patton, Jr (11 out of 12 patents)

4.  Myung-Gi Baek (10 out of 10 patents)

5.  John M Peterson (8 out of 11 patents)

Please report any incorrect information to [email protected]
Loading…